TWD 12.65
(-1.94%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 1.03 Million TWD | -61.46% |
2022 | 2.68 Million TWD | 0.0% |
2021 | - TWD | 0.0% |
2020 | - TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 2.35 Million TWD | 100.0% |
2024 Q1 | 2.35 Million TWD | 356.63% |
2023 Q2 | - TWD | 0.0% |
2023 Q4 | 516.49 Thousand TWD | 0.0% |
2023 FY | 1.03 Million TWD | -61.46% |
2023 Q1 | - TWD | -100.0% |
2023 Q3 | 516.49 Thousand TWD | 0.0% |
2022 Q3 | 1.34 Million TWD | 0.0% |
2022 FY | 2.68 Million TWD | 0.0% |
2022 Q4 | 1.34 Million TWD | 0.0% |
2021 FY | - TWD | 0.0% |
2020 FY | - TWD | 0.0% |
2019 FY | - TWD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Allied Biotech Corporation | 720.43 Million TWD | 99.857% |
GeneFerm Biotechnology Co., Ltd. | 793.77 Million TWD | 99.87% |
Easywell Biomedicals, Inc. | 271.62 Million TWD | 99.62% |
TTY Biopharm Company Limited | 5.5 Billion TWD | 99.981% |
Synmosa Biopharma Corporation | 5.14 Billion TWD | 99.98% |
Orient EuroPharma Co., Ltd. | 4.59 Billion TWD | 99.978% |
Center Laboratories, Inc. | 1.39 Billion TWD | 99.926% |
Tien Liang BioTech Co., Ltd. | 459.99 Million TWD | 99.775% |
Orient Pharma Co., Ltd. | 889.91 Million TWD | 99.884% |
InnoPharmax Inc. | 46.07 Million TWD | 97.758% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 606.71 Million TWD | 99.83% |
Excelsior Biopharma Inc. | 771.56 Million TWD | 99.866% |
DV Biomed Co., Ltd. | 1.53 Billion TWD | 99.933% |
Foresee Pharmaceuticals Co., Ltd. | 195.03 Million TWD | 99.47% |
Handa Pharmaceuticals, Inc. | 1.1 Billion TWD | 99.907% |
UniPharma Co., Ltd. | 103.22 Million TWD | 98.999% |
Anxo Pharmaceutical Co., Ltd. | 939.94 Million TWD | 99.89% |
Alar Pharmaceuticals Inc. | 469.27 Million TWD | 99.78% |
Winston Medical Supply Co., Ltd. | 709.07 Million TWD | 99.854% |
Bioray Biotech Co., Ltd | 191.83 Million TWD | 99.462% |
TSH Biopharm Corporation Limited | 810.91 Million TWD | 99.873% |